For at least a year, Eli Lilly and Co. provided information to doctors about the blood-sugar risks of its drug Zyprexa that did not match data the company circulated internally when it first reviewed its clinical trial results, according to company documents. In response to questions about the difference between its first view of the data and its subsequent public description, Lilly issued a statement Wednesday saying the later figures were accurate and the information in February 2000 was out of context. In Wednesday’s statement, the company said that after the February 2000 memo, it re-examined its clinical trial results and found errors in its “final, standard quality check of the data.”>>> Discuss This Story
